Sapheon, Inc. Announces Completed Enrollment in VenaSeal™ eSCOPE Study

Published: Sep 12, 2012

MORRISVILLE, N.C.--(BUSINESS WIRE)--Sapheon Inc. announced completed enrollment and first follow-up data in its European Sapheon Closure System Observational ProspectivE (eSCOPE) study. The single-arm, multi-center post-market study includes nine physicians at seven sites treating 67 patients from the UK, Germany, Demark and The Netherlands. Sapheon’s VenaSeal treatment uses a proprietary medical adhesive and delivery system to close the saphenous vein, eliminating the need for surgery, ablation, sedatives, anesthesia, post procedure compression stockings, and the use of chemical sclerosants.

Back to news